サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1317653

免疫抑制剤市場：機能、薬効分類、投与経路、エンドユーザー別-2023-2030年の世界予測

Immunosuppressant Drugs Market by Function, Drug Class, Route of Administration, End User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 190 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
免疫抑制剤市場：機能、薬効分類、投与経路、エンドユーザー別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

免疫抑制剤の世界市場は大きく成長すると予測され、2023年には11億1,621万米ドルが予測され、CAGRは6.34%、2030年には驚異的な17億1,928万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の免疫抑制剤市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.免疫抑制剤の世界市場規模および予測は？

2.予測期間中、世界の免疫抑制剤市場を形成するCOVID-19の阻害要因と影響は？

3.免疫抑制剤の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.免疫抑制剤の世界市場における競争戦略は？

5.免疫抑制剤の世界市場における技術動向と規制の枠組みは？

6.免疫抑制剤の世界市場における主要ベンダーの市場シェアは？

7.免疫抑制剤の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • ライフスタイルの変化による自己免疫疾患の有病率の増加
      • 肺、腎臓、肝臓、膵臓などの臓器移植手術の件数が増加
      • 組織工学と臓器移植の改善
    • 抑制要因
      • 複雑な規制プロセス
    • 機会
      • 新規薬物療法の開発
      • 腫瘍免疫学と規制当局の承認における最近の進歩
    • 課題
      • 個別化免疫抑制療法に伴う合併症
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 免疫抑制剤市場：機能別

  • 自己免疫疾患
    • 局所性自己免疫疾患
    • 全身性自己免疫疾患
  • 臓器移植

第7章 免疫抑制剤市場薬物クラス別

  • 抗増殖剤
  • カルシニューリン阻害剤
  • mTOR阻害剤
  • ステロイド

第8章 免疫抑制剤市場：投与経路別

  • 静脈内
  • オーラル

第9章 免疫抑制剤市場：エンドユーザー別

  • 診療所
  • 病院
  • 老人ホーム
  • 臓器移植センター
  • リハビリテーションセンター

第10章 南北アメリカの免疫抑制剤市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の免疫抑制剤市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの免疫抑制剤市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第14章 掲載企業一覧

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2022 VS 2030 (%)
  • FIGURE 5. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
  • FIGURE 6. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
  • FIGURE 7. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2022 VS 2030 (%)
  • FIGURE 8. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 9. IMMUNOSUPPRESSANT DRUGS MARKET DYNAMICS
  • FIGURE 10. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. IMMUNOSUPPRESSANT DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 19. IMMUNOSUPPRESSANT DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. IMMUNOSUPPRESSANT DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 5. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 6. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY LOCALIZED AUTOIMMUNE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ORGAN TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ANTIPROLIFERATIVE AGENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY CALCINEURIN INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY MTOR INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STEROID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 16. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY OLD AGE HOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ORGAN TRANSPLANT CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY REHABILITATION CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. IMMUNOSUPPRESSANT DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 234. IMMUNOSUPPRESSANT DRUGS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 235. IMMUNOSUPPRESSANT DRUGS MARKET LICENSE & PRICING
目次
Product Code: MRR-434CCDA051EE

The Global Immunosuppressant Drugs Market is forecasted to grow significantly, with a projected USD 1,116.21 million in 2023 at a CAGR of 6.34% and expected to reach a staggering USD 1,719.28 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Immunosuppressant Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Immunosuppressant Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Function, market is studied across Autoimmune Diseases and Organ Transplant. The Autoimmune Diseases is further studied across Localized Autoimmune Disease and Systemic Autoimmune Disease. The Autoimmune Diseases is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Antiproliferative Agent, Calcineurin Inhibitor, mTOR Inhibitor, and Steroid. The mTOR Inhibitor is projected to witness significant market share during forecast period.

Based on Route of Administration, market is studied across Intravenous and Oral. The Intravenous is projected to witness significant market share during forecast period.

Based on End User, market is studied across Clinic, Hospital, Old Age Home, Organ Transplant Center, and Rehabilitation Center. The Clinic is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Immunosuppressant Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Immunosuppressant Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Immunosuppressant Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Immunosuppressant Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Immunosuppressant Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Immunosuppressant Drugs Market?

6. What is the market share of the leading vendors in the Global Immunosuppressant Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Immunosuppressant Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Immunosuppressant Drugs Market, by Function, 2022 vs 2030
  • 4.3. Immunosuppressant Drugs Market, by Drug Class, 2022 vs 2030
  • 4.4. Immunosuppressant Drugs Market, by Route of Administration, 2022 vs 2030
  • 4.5. Immunosuppressant Drugs Market, by End User, 2022 vs 2030
  • 4.6. Immunosuppressant Drugs Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of autoimmune disease due to changing lifestyles
      • 5.1.1.2. Growing number of organ transplantation procedures for lungs, kidneys, liver, pancreas, and other
      • 5.1.1.3. Improvements in tissue engineering and organ transplantations
    • 5.1.2. Restraints
      • 5.1.2.1. Complicated regulatory processes
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of novel drug therapies
      • 5.1.3.2. Recent advances in immuno-oncology and regulatory approvals
    • 5.1.4. Challenges
      • 5.1.4.1. Complications associated with the personalizing immunosuppressive therapy
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Immunosuppressant Drugs Market, by Function

  • 6.1. Introduction
  • 6.2. Autoimmune Diseases
    • 6.2.1. Localized Autoimmune Disease
    • 6.2.2. Systemic Autoimmune Disease
  • 6.3. Organ Transplant

7. Immunosuppressant Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Antiproliferative Agent
  • 7.3. Calcineurin Inhibitor
  • 7.4. mTOR Inhibitor
  • 7.5. Steroid

8. Immunosuppressant Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral

9. Immunosuppressant Drugs Market, by End User

  • 9.1. Introduction
  • 9.2. Clinic
  • 9.3. Hospital
  • 9.4. Old Age Home
  • 9.5. Organ Transplant Center
  • 9.6. Rehabilitation Center

10. Americas Immunosuppressant Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Immunosuppressant Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Immunosuppressant Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing